Tags : ATTRACTION-3 Study

ONO Pharmaceutical Reports Results of Opdivo (Nivolumab) in P-III ATTRACTION-3

Vartika Singh January 10, 2019

Shots: The P-III ATTRACTION-3 study involves assessing of Opdivo (involumab, IV) vs CT (docetaxel/paclitaxel) in patients with unresectable advanced or recurrent esophageal cancer or intolerant to fluoropyrimidine + PT-based drug […]readmore

Tags : ATTRACTION-3 Study

ONO Pharmaceutical Reports Results of Opdivo (Nivolumab) in P-III ATTRACTION-3

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ATTRACTION-3 Study

ONO Pharmaceutical Reports Results of Opdivo (Nivolumab) in P-III ATTRACTION-3

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company